Pivotal Therapeutics Inc (PVTTF: OTCQX International) |

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pivotal Therapeutics Inc (PVTTF: OTCQX International) | Pivotal Therapeutics announces changes to the Board of Directors Pivotal Therapeutics announces changes to the Board of Directors

Pivotal Therapeutics announces changes to the Board of Directors

Canada NewsWire

WOODBRIDGE, ON , May 14, 2014 /CNW/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF)(CSE:PVO) ("Pivotal" or "the Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease and overall health, today announced changes to its Board designed to increase its independence and enhance Pivotal's corporate governance at this stage of the Company's development.

Dr. Jackowski has stepped down as Chairman of Pivotal Therapeutics Inc. effective May 13, 2014 but remains a director and the Chief Scientific Officer of the Company and will continue to leverage his wealth of experience and contacts in the biotechnology and pharmaceutical industry to advance Pivotal's clinical, R&D and business development activities.

John S. Gebhardt , an independent director of the Company, has been appointed as non-executive Chairman to fill the vacancy. A member of Pivotal's Board of Directors since 2011, Mr. Gebhardt has over thirty years of experience in the financial and securities industry.  A former Managing Director at Knight Capital Group, Mr. Gebhardt also worked at PaineWebber for over 20 years where he was a Managing Director, prior to it becoming part of UBS Financial Services.  Mr. Gebhardt has also been involved in extensive public service serving on a public school board for 12 years and currently serving on the Board of Directors of both his county's Boys & Girls Clubs, as well as the Educational Foundation of Osceola County , and is currently serving as an elected public official in the State of Florida .

Dr. Jackowski commented, "On behalf of my fellow directors, I would like to congratulate John on his appointment as Chairman. The Company has benefited from his insights and guidance over the years and we look forward to continuing to work closely with him on the Board. We believe that this recent change demonstrates that management and the Board continues to act in the best interest of shareholders and other stakeholders."

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX:PVTTF)(CSE:PVO) specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product VASCAZEN ® is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. OMAZEN ® is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. OMAZEN ® is a patented product available for sale and distribution in Canada

About VASCAZEN ®

VASCAZEN ® is currently available in the U.S. as a prescription only medical food specifically formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients. VASCAZEN ® is a > 90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series of both U.S. and foreign patents.

VASCAZEN ® has been clinically shown to correct an Omega-3 deficiency within eight weeks of treatment with positive concomitant effects on the lipid profiles, mainly a 48% reduction of triglycerides and an increase of HDL without negative impact on the LDL-C lipid profile.    VASCAZEN ® 's results were achieved with a dose of 3 grams of EPA and DHA per day of a prescription grade, high purity Omega-3.

Disclosure Notice
The information contained in this document is as of May 14, 2014 . This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSE listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.

SOURCE Pivotal Therapeutics Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Awards Spotlight Luxury Hospitality's Reach

Updated Category News Views 90

Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...

Continue Reading
COP31 Tests Whether Climate Warnings Move Power Systems

Updated Category News Views 101

A weather alert that never reaches the control room is just expensive wallpaper. That was the useful, unsentimental thread running through a COP31 side event in Ankara on November 13: climate diplomacy is not worth much if grid operators, project owners and financiers do not change what they do when the forecast turns ugly. Implementation Means Changing Operations COP31...

Continue Reading
iHeart's 65% Plunge Brings a Fraud Probe Into Focus

Updated Category News Views 71

November 10 did not merely bruise iHeartMedia shareholders; it left the stock closing at $0.61 after a decline of more than 65%. That kind of move gets everybody’s attention, including plaintiffs’ lawyers, and Wolf Haldenstein Adler Freeman & Herz LLP has opened an investigation into potential securities fraud claims involving iHeartMedia, its officers, and its...

Continue Reading
Healthcare's Prevention Puzzle Needs Better Incentives

Updated Category News Views 100

When Savings Belong to the Next Plan A patient changing insurance plans can turn prevention into nobody’s asset. That is the uncomfortable little engine inside Russell Greenfield’s recent argument: an insurer may pay today for a program that helps prevent chronic illness, only to watch the eventual savings land with another plan after the member moves on. The person...

Continue Reading
Zensar’s AI Forum Puts Operations Before the AI Hype

Updated Category News Views 111

Johannesburg’s AI conversation seems to be shedding its costume jewelry at last. Zensar’s invitation-only CIS Converge 2026 forum, held on November 20, put the attention where it belongs: not on breathless demos, but on whether companies can turn AI into sturdier operations, better customer experiences, and something resembling a measurable return. That is a healthier...

Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board

Updated Category News Views 65

Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 49

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
Mason Adds Nonprofit Expertise to Institutional Bench

Updated Category News Views 65

Endowment committees rarely need more noise; they need somebody who has actually sat through the uncomfortable votes. Mason Investment Advisory Services has hired Rebecca “Becky” Farnsworth, CFA, as a senior investment consultant, and this looks like a practical addition rather than the usual chest-thumping personnel announcement. Her stated focus will be...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
AI Shopping Answers Are Becoming Retail's New Shelf

Updated Category News Views 67

Retail’s front door is quietly being moved by a machine, and plenty of big chains appear to be staring at the old entrance. Bain’s latest work lands on an uncomfortable point: owning market share does not guarantee a retailer gets named when an AI assistant answers a shopper’s question. That ought to rattle management teams more than the usual holiday-season...

Continue Reading

Top 5 Most Recently Viewed Articles

Latham Plunge Pools Earns Top Honors as Innovative Retail Design

Updated Category News Views 252

Latham Plunge Pools: Celebrating Innovation in Outdoor Living Latham Group, Inc. (NASDAQ:SWIM), the leading designer and manufacturer of in-ground swimming pools, has recently been recognized for its exceptional contribution to the backyard experience. Their latest achievement, the "Most Innovative Product for Retailers" award, was proudly received at the prestigious...

Continue Reading
HF Sinclair Corporation Announces Upcoming Earnings Webcast

Updated Category News Views 120

HF Sinclair Corporation Earnings Announcement HF Sinclair Corporation (NYSE: DINO) is preparing to share its financial results for the third quarter, which ends on September 30, 2024. This important announcement is set for October 31, 2024, and will take place before the market opens on the NYSE. Details of the Earnings Release All investors and interested individuals...

Continue Reading
Verde Resources Unveils VerdePlus, Paving the Way for Green Infrastructure

Updated Category News Views 135

Verde Resources Inc. Introduces VerdePlus for Sustainable Solutions Verde Resources Inc. (OTCQB: VRDR) is proud to announce a transformative step in their efforts towards sustainable infrastructure with the launch of VerdePlus Inc. This innovative subsidiary, developed through a partnership with Nature Plus Inc. (NPI), aims to set new standards in low-carbon construction...

Continue Reading
East Palestine Settlement Center Closure: What You Need to Know

Updated Category News Views 229

Important Closure of the East Palestine Settlement Center The East Palestine Settlement Center, specifically created to aid those affected by a recent train derailment, will be closed on Friday, January 17. This decision comes in response to pending traffic restrictions expected in the surrounding area, which may hinder access to the facility. Rescheduling and Future...

Continue Reading
Aditx Therapeutics Faces Challenges with Stock at $0.18 Low

Updated Category News Views 280

Aditx Therapeutics Faces Significant Stock Decline Aditx Therapeutics Inc (ADTX) has recently encountered a challenging period as its stock price plummeted to a 52-week low of $0.18. This significant decrease illustrates a dramatic 1-year change of -99.9%. Such a downturn highlights the tumultuous state of the biotech company, which is currently grappling with a market...

Continue Reading